Background
Introduction
Tight junctions (TJs) serve a crucial role in maintaining homeostasis and the cell-cell interactions between epithelial cells. These junctional stuctures block the free diffusion of lipids and proteins by regulating the flow of small ions between cells [1] [2] [3] . TJs also serve an important role in maintaining epithelial cell architecture and retaining apical-basolateral polarity [4] .
Claudin 1 forms the backbone of TJs, and has been shown to be solely responsible for the epithelial cell barrier function, i.e. separating the internal milieu from the external environment [5] . In cancer, the role of claudin 1 appears to be dichotomous; upregulated in some cancers [6] [7] [8] [9] [10] [11] [12] and downregulated in others [13] [14] [15] [16] . Moreover, claudin 1 has recently been shown to promote cancer progression and metastasis in several cancers including colon, liver and squamous cell carcinomas [7, 10, 17] . In breast cancer, its role remains a bit of an enigma. Suggested to be a tumor suppressor, down regulation of the claudin 1 gene (CLDN1) has been associated with estrogen receptor (ER) positivity [18] and poor prognosis in invasive breast cancer [15] . However, high levels of claudin 1 have recently been demonstrated in a small but significant group of breast cancers, including the largely aggressive basal-like subtype [18] .
The mechanisms by which CLDN1 is regulated in breast cancer are largely unknown. To date, no CLDN1 mutations have been identified either through promoter sequencing or exome sequencing analyses. However, a search of The Cancer Genome Atlas (TCGA) database (a large human invasive breast cancer cohort), revealed CLDN1 was one of a group of highly methylated genes [19] , suggesting that epigenetic factors may also play a significant role in the regulation of this gene in some breast cancer subtypes.
Recently, genome-wide analyses have revealed that as many as 95% of human genes undergo alternative splicing [20] and that mis-splicing events (mis-regulation) are often related to cancer and other human diseases. Alternative splicing is known to give rise to transcript variants and can result in the encoding of different protein isoforms. CLDN1 is located at 3q28-q29 and is comprised of four exons. It has one classical transcript (3.4kb), which codes for a functional 21kD protein [21] . A second non-coding transcript has also been identified, and does not give rise to a translated protein product [21] . In the present study, we investigated whether CLDN1 transcript variants occur in human invasive breast cancers. We have identified a number of CLDN1 transcript variants, and propose that other epigenetic factors such as transcript variant utilization may be another mechanism by which CLDN1 is regulated in breast cancer.
Materials and Methods

Human breast tissue
Twelve human invasive breast cancers used in the current study were obtained from the Manitoba Breast Tumour Bank (MBTB, Department of Pathology, University of Manitoba), which operates with the approval from the Faculty of Medicine, University of Manitoba, Research Ethics Board. Studies were carried out with the approval of the Bannatyne Campus, University of Manitoba, Research Ethics Board. Written informed consent was obtained from all participants. Collection, handling and histo-pathological assessment of tumor tissues have been previously described [22, 23] . Six normal breast tissue samples, derived from reduction mammoplasty procedures on healthy women, were also obtained from the MBTB.
RNA extraction and sequencing of transcripts
Total RNA was extracted from 12 invasive human breast tumors and subjected to RT-PCR analysis using primers flanking the coding region of CLDN1 (Table 1) . Total RNA was extracted from frozen tumor tissue samples using the RNAeasy kit (Qiagen Corporation, Mississauga, Canada) and quantitated spectrophometrically using a NanoDrop 2000 (ThermoFisher Scientific, Waltham, MA, USA). RNA was reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad Laboratories Inc., Mississauga, Canada) according to the manufacturer's instructions. PCR amplification reaction mixtures contained 50ng of reverse transcribed total RNA, 20mM Tris-HCl, pH 8.4, 50mM KCl, 2.5mM MgCl 2 , 0.2uM of forward and reverse primers (Table 1A) , 0.2mM each dNTP, and 1U of Platinum Taq DNA polymerase (Life Technologies, Burlington, Canada). The cycle profile consisted of denaturation at 94°C for 4 min., followed by 50 cycles of 94°C for 30s, 55°C for 30s, and 72°C for 45s and a final extension step of 72°C for 5 min. The PCR products were analyzed by 1% agarose gel by electrophoresis and stained with RedSafe nucleic acid staining solution (iNtRON Biotechnology, FroggaBio, Toronto, Canada). Bands selected for sequencing were excised from the gel and purified using the QIAquick Gel Extraction kit (Qiagen Corporation) and subcloned using the TOPO TA cloning kit (Life Technologies). Sequencing of the PCR product positive clones was conducted at The Centre for Applied Genomics (TCAG, Toronto, Canada).
Genomic DNA extraction and sequencing of exon coding regions
Genomic DNA was extracted from frozen tissue by overnight digestion at 55°C with Proteinase K (Roche Diagnostics, Indianapolis, IN, U.S.A.) followed by phenol/chloroform extraction. The DNA concentration was measured spectrophometrically using a NanoDrop 2000 (ThermoFisher Scientific). PCR amplification of the exon coding regions was conducted using 150ng of genomic DNA, using 1U of Platinum Taq DNA polymerase and 0.2uM of forward and reverse primers (Table 1B) . The cycle profile consisted of denaturation at 94°C for 5 min., followed by 45 cycles of 94°C for 45s, 58°C for 30s, and 72°C for 1 min. and a final extension step of 72°C for 5 min. The PCR products were analyzed by 1% agarose gel electrophoresis and bands were excised and purified from the gel using the QIAquick Gel Extraction kit (Qiagen Corporation). Sequencing of the purified products was conducted at The Centre for Applied Genomics (TCAG, Toronto, Ontario).
Identification of transcript variants and SNPs
Clustal Omega [24] was used to align the sequences of the transcript variants with the human CLDN1 mRNA sequence from GenBank (NM_021101.4), and the sequences from the exon coding regions with the CLDN1 gene sequence from Ensembl (ENSG00000163347, [21] ). Sequence variants were matched with their dbSNP reference SNP identifier (http://www.ncbi. nlm.nih.gov/SNP).
Immunohistochemistry (IHC)
Tumor sections (5 μm) were cut from paraffin-embedded tissue, mounted on Fisherbrand Superfrost/plus slides (ThermoFisher Scientific) and stained with the rabbit polyclonal claudin 1 antibody (Life Technologies) at a dilution of 1:150. This antibody has been previously validated for specificity and sensitivity in our laboratory [18] . IHC was performed as recently reported [25] using an automated tissue immunostainer (Discovery Staining Module, Ventana Medical Systems, AZ, USA). Briefly, sections were dewaxed in two xylene baths, taken through a series of alcohols, rehydrated and then submitted to heat-induced antigen retrieval for 8 min in the presence of a citrate buffer (CC1, Ventana Medical Systems) using the automated tissue immunostainer (Discovery Staining Module, Ventana Medical Systems). Primary antibodies were applied for 60 min and secondary antibodies for 32 min. Positive staining for claudin 1 protein was assessed using semi-quantitative scoring (Hscores). H-scores were derived from both staining intensity (scale 0-3) and percentage of positive cells (0-100%), which when multiplied, generated a score ranging from 0-300. Tissue microarray (TMA) staining was evaluated independently by two investigators (AB, CP) and where discordant, cases were re-evaluated jointly.
Statistical Analysis
Frequency of SNPs in human breast tumors versus the normal population was analysed using the Fisher's Exact Test (GraphPad Prism version 6.07, GraphPad Software, La Jolla California USA).
Results
Identification of CLDN1 transcript variants in human invasive breast cancer
To investigate CLDN1 transcript variants in human invasive breast cancer, RT-PCR analysis was performed on breast tumor samples as described in the methods section. In addition to the full length transcript, a number of smaller PCR products were observed in several tumor samples. A representative result is depicted in Fig 1. In multi-template PCRs, rare templates can often be diluted out, or template concentration can be biased by differences in amplification efficiency [26] . Thus, it was not possible to gel purify sufficient quantities of DNA in order to clone and sequence all products. However, as proof of principle, sequencing of some PCR products revealed several shorter cDNA products (Fig 2) . Four were selected for further investigation. These were verified as CLDN1 transcript variants. The largest PCR product, V1 (representing the largest CLDN1 transcript variant), was the result of an alternate splice site at the 3' end of exon 1 but which exhibited normal splicing events at exon 2 (Fig 2) . Another, designated CLDN1 transcript variant, V2, displayed alternate splice sites in exon 1 and 2, while alternate splice sites in exons 1 and exon 4 were identified in the two other transcript variants, V3 and V4 (Fig 2) . Interestingly, the V1 results in premature stop codons and is expected to be degraded through nonsense-mediated decay. Thus, this perhaps contributed to the relatively lower level of the claudin 1 full length transcript in tumors #5, 7, 11 and 12 (Fig 1) . (Table 1) flanking the coding regions of CLDN1, 3, and 4. The expected full length cDNA products (representing the classical transcripts) for CLDN1 and CLDN4 (700 bases and 706 bases respectively) was evident in all tumors. However, no CLDN3 transcript was detected in some of the breast tumors (middle panel; lanes 4, 10, 11). Colored arrows indicate CLDN1 PCR products which were verified by Sanger sequencing: yellow arrow, transcript variant 1 (V1) is 615 bp; red arrow, transcript variant 2 (V2) is 440bp; blue arrow, transcript variant 3 (V3) is 362 bp; and green arrow, transcript variant 4 (V4) is 217 bp. In the lower panel, the product indicated by the black arrow, was a non-specific band and had no sequence homology to CLDN4. doi:10.1371/journal.pone.0163387.g001
To determine whether transcript variants were a common occurrence among members of the claudin protein family, particularly among those members which have been shown to be up regulated in breast cancer, claudin 3 and claudin 4 [27, 28] , RT-PCR analysis was carried out. Only the expected, full length PCR products for both of CLDN3 and CLDN4 (706 bp for CLDN3, and 695 bp for CLDN4) were identified, with the exception of a non-specific product for CLDN4 which, when sequenced, lacked any sequence homology to CLDN4 (Fig 1) .
Expression of transcript variants in normal human breast tissue and breast tumors
To determine whether transcript variants were expressed in normal breast tissue samples, primers were designed to amplify three CLDN1 transcript variants, V1, V2 and V3. PCR analysis was conducted on six normal breast tissue samples and six randomly selected breast tumor samples (Fig 3) . CLDN1 transcript variant, V1, was amplified in breast cancer tissue (2/6 tumors) as well as normal human breast tissue samples (3/6). Transcript variant, V3, was detected in both breast cancer tissue (3/6 tumors) and in normal human breast tissue samples (4/6). However, V2 was present only in breast tumor samples (3/6). This transcript variant was absent in the normal breast tissue samples. Forward primers were designed to specifically amplify V1 and V2 CLDN1 transcripts. The reverse primer flanked the coding region of CLDN1 mRNA and was identical to the one used for the PCR amplification shown in Fig 1. A reverse primer was specifically designed to amplify the V3 transcript variant and used in conjunction with the CLDN1 forward primer (Table 1) . B. Differential expression of transcript variants. V1 was amplified in both breast cancer (2/6 tumors) and normal tissue samples (3/6). However, V2 was only evident in the breast tumors (3/6). V3 was detected in both tumors (3/6 tumors) and normal tissue (4/6). Gapdh was used as a control for the RT-PCR reaction. (blk = no template). PCR analysis was performed on the six remaining tumors, however only four were evaluated as the material for two were exhausted. V1 was amplified in a total of 4/10 tumors, V2 in 5/10 tumors, while V3 was amplified in 6/10 tumors ( Table 2) .
Identification of SNPs in CLDN1
To determine whether the transcript variants were a consequence of genomic DNA deletions, PCR analyses were conducted on each of the four CLDN1 exons using genomic DNA from each of the 12 tumors as templates. Sequence analysis of the PCR products failed to identify any deletions (not shown). However, previously identified heterozygous SNPs were identified (Table 2) in some cases. The SNP (rs17429833), located in the 5' untranslated region, and identified in only one of the 12 breast cancer specimens (tumor #12 , Fig 4) was found to be present in 5.4% of the normal population (University of California Santa Cruz, UCSC, database). A second SNP (rs3172404) was identified in the 3' untranslated region of the same tumor as well as in two additional tumors (tumors #2, #9; Fig 4) . The frequency of occurrence of this SNP in the tumors was calculated to be equivalent to that for the normal population. However, a synonymous SNP (rs72466472) detected in exon 1 of two tumors (tumor #5, #11) exceeded the normal frequency of occurrence (8.3% vs 2.6%; UCSC database) found in the normal population (Fig 4) . Conversely, a second synonymous SNP (rs9869263) was identified in exon 2, at a frequency very much below (4.2%) that of the normal population (19%). Of notable interest was the identification of a rare missense variant (rs140846629) in exon 2 of tumor #4. The frequency of this allele (4.2%) was significantly higher (p<0.05) than that calculated for the normal population (0.15%, UCSC SNP database). 1-3 ). H scores were further categorized as 0-15 = -(neglible); 20-75 = + (low); 80-150 = ++ (moderate); 155-300 = +++ (high). There was a trend towards high claudin 1 levels (3/4) being associated with ER-tumors, as previously described [18] , but no direct correlation with transcript variant and ER status was evident. 
Tumor
Immunohistochemical analysis of claudin 1 protein in breast tumors
Next we wanted to examine whether there was a relationship between claudin 1 protein level in the breast cancer specimens and the presence of transcript variants or SNPs. To determine whether claudin 1 protein levels were associated with the presence (or absence) of CLDN1 transcript variants, immunohistochemical (IHC) analysis of breast tumors was determined using a Table 1 ). The cDNA position of the SNPs are shown and designated by their corresponding Reference SNP (rs) numbers. The frequency of the missense SNP detected in exon 2, was significantly higher in the breast tumors than predicted for the normal population (p< 0.5; two-tailed Fisher's Exact Test). Fig 5) . Results from this analysis revealed that claudin 1 protein levels in the 12 breast tumors ranged from not detectable or low (5/12 tumors) to very high (4/12 tumors). However, though no relationship between the claudin 1 protein levels and the presence of transcript variants or SNPs was overtly evident, tumors #5 and 7, which also expressed low levels of mRNA (Fig 1) , showed negligible staining of the claudin 1 protein by IHC.
Discussion
The deregulation of CLDN1 in different cancers is not well understood. Claudin 1 has been clearly demonstrated to directly promote carcinogenesis in some cancers [10, [29] [30] [31] [32] . In others, such as esophageal squamous cell carcinoma [33] , lung [34] , prostate [35] , melanocytic neoplasia [36] and breast cancers [28, 37] , claudin 1 appears to demonstrate tumor suppressor activities. Further, in breast cancer, a down regulation of CLDN1 has more frequently been associated with invasiveness and poor patient prognosis [15] . However, an up regulation of CLDN1 in specific breast cancer subtypes, including the highly aggressive basal-like breast cancer, has now been demonstrated by us and others [18, 25, 38, 39] . The mechanism by which CLDN1 is regulated in breast cancers is largely unknown. Yet, to date, no mutations have been identified that can be attributed to the silencing of this gene during breast cancer progression.
It is now well recognized that the effect of the genome and epigenome can strongly influence each other in cancer, and that SNPs, transcript variants and methylation are important factors in the regulation of several cancers [40] . It is also recognized that multiple modes of alternative splicing exist, such as alternative 5 0 or 3 0 splice-site usage, as well as differential inclusion or skipping of particular exons, which result in transcript variants. It has been shown that >20,000 single nucleotide variants can disrupt splicing, and that nonsense, missense and synonymous exonic variants can also affect alternative splicing, some as far as 300 base pairs from the splice sites [41] . Furthermore, epigenetic factors play an important role in therapeutic responses as demonstrated by the altered responses to estrogen therapy attributed in part to transcript variants and SNPs [42, 43] in some breast cancer patients.
The 17 kb CLDN1 gene codes for the classical 3.4kb transcript which translates into the intact functional protein. It also gives rise to a non-coding transcript with intron retention [21] . Several (over 80) spliced expressed sequence tags (ESTs) have also been identified (University of California, Santa Cruz (UCSC) Genome browser [44] ). In this study, we report for the first time, numerous CLDN1 transcript variants in breast cancer. Each CLDN1 transcript variant identified was shorter in length than the expected cDNA product (700bp). Comparison analysis with other members of the claudin family, CLDN3 and CLDN4, whose genes are overexpressed in breast cancer [27, 28] , revealed that the transcript variants were unique to CLDN1. We selected four of the transcript variants (V1, V2, V3, and V4) for further analysis. The splicing sites and patterns identified in these variants were novel and were not, to our knowledge, found to be previously reported in any existing available database. Moreover, two of the variants were identified in some normal tissue as well, suggesting the possibility that the presence of these variants may predispose a person to disease. However, future studies are necessary to show such a causal link. Intriguingly, we observed that one of the transcript variants, V2, was only detected in tumor samples and not in any of the normal breast tissue. As well, a follow-up of the potential significance and consequences of the presence of this transcript variant in breast cancer is warranted. Unfortunately, at this time verification of any putative proteins generated from these transcripts has not been possible due to the lack of commercial antibodies to the N-terminus region of claudin 1. In addition, any proteins resulting from the translation of transcript variants due to deletions could be missed due to mis-match with the c-terminal classical claudin 1 antibody.
A number of CLDN1 SNPs were also identified in the breast tumor specimens. The synonymous SNP, rs9869263, that we identified in exon 2 in the present study, was reported to occur at a frequency of 2.6% of alleles in the normal population [44] . In the 12 breasts cancers analyzed, 2/12 or 17% of tumors (8.3% of alleles) were positive for this SNP. This is not the first time this SNP has been associated with cancer. The rs9869263 genotype (c.369C>T) was recently shown to be related to differentiation and tumor stage and increased risk of colon cancer [45] . Another SNP, the rs17501976 polymorphism in CLDN1 was also shown to impact colon cancer risk. However, in the latter case it was shown to be significantly associated with a decreased susceptibility to colorectal cancer in a Chinese population [46] .
A search of the Ensembl database revealed nearly 3000 CLDN1 genetic variants, with over 900 within the gene sequence [21] , and some of these SNPs associated with disease. For example, one such SNP, rs9290927, was recently shown to enhance the development of a blood brain barrier disorder [47] . Others, found in the CLDN1 promoter region, have been shown to confer susceptibility to hepatitis C virus infection [48] . Interestingly, with regard to CLDN1 SNPs in breast cancer, to date, only one mutation, p.V85G, has been identified in one of 993 patient samples analyzed in the Cancer Genome Atlas project [49] .
A c.370G>A mutation, which resulted in the p.A124T substitution, and which was identified in only one out of the twelve breast cancer tumor specimens analyzed, was viewed as a rare polymorphism (rs140846629; frequency of 0.0015), as calculated in both the Ensembl and the Washington database [21, 50] . Notably, this amino acid change has been predicted to be a possibly damaging substitution (based on the assigned PolyPhen 2 score of 0.542 [51] ), not specifically only in breast cancer but in other cancers as well. Even more intriguing was the observation that the A124T substitution was the only mutation detected in the CLDN1 gene in 1 of 169 brain lower grade glioma, and in 1 of 132 stomach adenocarcinoma cases, but not in over 900 breast cancers (The Cancer Genome Atlas datasets, [49] ). Since we identified this A124T mutation in one in 12 breast tumor samples, it is possible that this variant may occur more frequently in our patient cohort and is important to disease development within this population. As well, our analyses suggest that there is a relationship between the SNP, rs3172404, and the presence of the transcript variants, V1, V2, and V3 in tumors (Table 2 , tumors 2, 9, 12). However, whether this SNP is related to the generation of these transcript variants will need to be followed up.
We further investigated whether there was an association between ER positivity and transcript variant expression within this cohort, since our previous work showed a relationship between ER status and claudin 1 levels [18] . Our analysis did not reveal any significant correlation between the presence of the claudin 1 transcript variants and ER status. However, this lack of correlation could merely be attributed to the small sample size, which limited the ability to conduct rigid statistical analyses.
Recent reports suggest that hypermethylation may be a partial mechanism of CLDN1 silencing in breast cancer [52] . In particular, this was observed in the luminal-like ER+ breast cancers which exhibits low CLDN1 expression. We have previously shown in vitro that the human breast cancer cell line, MCF7, that displays low endogenous claudin 1 levels was hypermethylated compared to the T47D human breast cancer cell line that expresses high claudin 1 levels [53] . Here, in the present study, we now show that in breast cancer there are numerous CLDN1 transcript variants suggesting that alternate splicing may be another mechanism of CLDN1 deregulation. We also observed a trend towards increased transcript variants with the more aggressive ER-tumors, suggesting that variant presence could be related to tumor stage. Altogether, these studies suggest that epigenetic factors may play a role in CLDN1 regulation in breast cancer. However, these observations warrants a larger follow-up study to determine whether CLDN1 transcript variants are associated with certain breast cancer subtypes and will allow us to ascertain the potential use of these transcript variants as biomarkers in predicting tumor development and outcome in breast cancer. 
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